Epidemiology of cardiovascular complications in type 2 diabetes mellitus, Acta Diabetol, vol.40, issue.2, pp.358-61, 2003. ,
Glucose-lowering therapies in patients with type 2 diabetes and cardiovascular diseases, Eur J Prev Cardiol, vol.26, issue.2_suppl, pp.73-80, 2019. ,
Assessing the cardiovascular safety of diabetes therapies, N Engl J Med, vol.359, issue.11, pp.1092-1097, 2008. ,
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes, N Engl J Med, vol.356, issue.24, pp.2457-71, 2007. ,
Academic perspectives on the United States Food and Drug Administration's guidance for industry on diabetes mellitus, Contemp Clin Trials, issue.5, pp.411-414, 2010. ,
Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes, Diabetes, vol.47, issue.11, pp.1663-70, 1998. ,
Alogliptin after acute coronary syndrome in patients with type 2 diabetes, N Engl J Med, vol.369, issue.14, pp.1327-1362, 2013. ,
Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial, Lancet, vol.2015, issue.9982, pp.2067-76 ,
URL : https://hal.archives-ouvertes.fr/hal-01745763
Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis, Lancet, vol.2012, issue.9854, pp.1662-73 ,
Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study, Lancet, vol.2012, issue.9844, pp.807-821 ,
Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes, Clin Ther, vol.30, issue.3, pp.499-512, 2008. ,
EXamination of cArdiovascular outcoMes with alogliptIN versus standard of carE in patients with type 2 diabetes mellitus and acute coronary syndrome (EXAMINE): a cardiovascular safety study of the dipeptidyl peptidase 4 inhibitor alogliptin in patients with type 2 diabetes with acute coronary syndrome, Am Heart J, vol.162, issue.4, pp.620-626, 2011. ,
A new equation to estimate glomerular filtration rate, In Ann Intern Med, United States, vol.150, pp.604-616, 2009. ,
A proportional hazards model for the subdistribution of a competing risk, J Am Stat Assoc, vol.94, pp.496-509, 1999. ,
Clinical pharmacology of alogliptin ,
, inhibitor, for the treatment of Type 2 diabetes, Expert Rev Clin Pharmacol, vol.2, issue.6, pp.589-600, 2009.
Effects of alogliptin in chronic kidney disease patients with type 2 diabetes, Intern Med, vol.53, issue.3, pp.195-203, 2014. ,
Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes, Clin Pharmacokinet, vol.54, issue.1, pp.1-21, 2015. ,
Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients, Pharmacoepidemiol Drug Saf, vol.27, issue.6, pp.660-667, 2018. ,
Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes, N Engl J Med, vol.373, issue.3, pp.232-274, 2015. ,
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus, N Engl J Med, vol.369, issue.14, pp.1317-1343, 2013. ,
Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial, Jama, vol.22, 2019. ,
Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial, Jama, vol.2019, issue.1, pp.69-79 ,
Dipeptidyl Peptidase-4 Inhibitors in Chronic Kidney Disease: A Systematic Review of Randomized Clinical Trials, Nephron, vol.2017, issue.2, pp.85-94 ,